The test allows to detect and monitor changes in circulating tumour fraction to determine early response to immunotherapy. Credit: CDC on Unsplash.

Technology company Tempus has introduced the new circulating tumour DNA (ctDNA) assay, xF Monitor, to be used only for research purposes.

The test is intended for detecting and monitoring changes in the circulating tumour fraction to determine early response to immunotherapy in advanced cancer patients.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

It is now accessible exclusively for research purposes for xF 105-gene and xF+ 523-gene liquid assays.

Using diverse genomic events, dynamically weighting somatic variant allele frequencies and copy number variants, the test measures quantitative molecular changes in the ctDNA tumour fraction.

It utilises germline information to inform these estimates.

The algorithm that powers xF Monitor, xF ctDNA tumour fraction, uses several single input models and weights their significance based on observed failure modes in the multimodal database of Tempus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Tempus chief scientific officer Kate Sasser said: “We are excited to add the xF Monitor assay to our comprehensive suite of precision medicine offerings here at Tempus. There has been tremendous progress in the utilisation of ctDNA for monitoring patient response to treatment, especially for immunotherapy.

“We are looking forward to bringing our xF Monitor assay forward as a diagnostic tool to help biopharma develop innovative medicines and physicians to tailor therapies for patients.”

The company will exhibit the xF Monitor assay at the Society for Immunotherapy of Cancer’s 38th Annual Meeting.

In July 2023, Tempus and TScan Therapeutics announced a collaboration for the development of a new companion diagnostic (CDx) test.